(Q37109209)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

David Ulmert

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Andrew Vickers

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

David Ulmert

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

268-278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc2351

4 January 2020

exact match

0 references

cites work

A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein

1 reference

Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue

31 March 2020

1 reference

Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.

31 March 2020

1 reference

Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen

31 March 2020

1 reference

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen

31 March 2020

1 reference

Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age

31 March 2020

1 reference

Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors

31 March 2020

1 reference

In Situ Hybridization of Prostate-Specific Antigen mRNA in Human Prostate

31 March 2020

1 reference

Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era

31 March 2020

1 reference

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study

31 March 2020

1 reference

Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer

31 March 2020

1 reference

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

31 March 2020

1 reference

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

31 March 2020

1 reference

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial

31 March 2020

1 reference

Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council

31 March 2020

1 reference

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.

31 March 2020

1 reference

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

31 March 2020

1 reference

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

31 March 2020

1 reference

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

31 March 2020

1 reference

The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations

31 March 2020

1 reference

Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial

31 March 2020

1 reference

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial

31 March 2020

1 reference

Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project

31 March 2020

1 reference

Age-specific reference ranges for serum prostate-specific antigen in black men.

31 March 2020

1 reference

Age specific prostate specific antigen reference ranges: population specific

31 March 2020

1 reference

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

31 March 2020

1 reference

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

31 March 2020

1 reference

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

31 March 2020

1 reference

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study

31 March 2020

1 reference

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

31 March 2020

1 reference

The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA.

31 March 2020

1 reference

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

31 March 2020

1 reference

Prostate-specific antigen velocity and prostate cancer gleason grade and stage

31 March 2020

1 reference

Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval

31 March 2020

1 reference

Age and racial distribution of prostatic intraepithelial neoplasia.

31 March 2020

1 reference

31 March 2020

Cancer statistics, 2007

1 reference

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

31 March 2020

1 reference

Cancer Detection and Cancer Characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) – Section Rotterdam

31 March 2020

1 reference

Radical prostatectomy versus watchful waiting in early prostate cancer

31 March 2020

1 reference

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial

31 March 2020

1 reference

Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer

31 March 2020

1 reference

Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?

31 March 2020

1 reference

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

31 March 2020

1 reference

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

31 March 2020

1 reference

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.

31 March 2020

1 reference

The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml

31 March 2020

1 reference

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis

31 March 2020

1 reference

The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia

31 March 2020

1 reference

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

31 March 2020

1 reference

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer

31 March 2020

1 reference

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue

31 March 2020

1 reference

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

31 March 2020

1 reference

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

31 March 2020

1 reference

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

31 March 2020

1 reference

Predictors of mortality after prostate-specific antigen failure

31 March 2020

1 reference

Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.

31 March 2020

1 reference

Metastatic prostate cancer with normal level of serum prostate-specific antigen.

31 March 2020

1 reference

Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition

31 March 2020

1 reference

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.

31 March 2020

1 reference

NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN

31 March 2020

1 reference

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995

31 March 2020

1 reference

Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy

31 March 2020

1 reference

PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis

31 March 2020

1 reference

Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques

31 March 2020

1 reference

Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy

31 March 2020

1 reference

PSA kinetics and PSA bounce following permanent seed prostate brachytherapy

31 March 2020

1 reference

PSA bounce predicts early success in patients with permanent iodine-125 prostate implant

31 March 2020

1 reference

PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup

31 March 2020

1 reference

Patterns and fate of PSA bouncing following 3D-CRT

31 March 2020

1 reference

Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis

31 March 2020

1 reference

Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?

31 March 2020

1 reference

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

31 March 2020

1 reference

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

31 March 2020

1 reference

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis

31 March 2020

1 reference

Comparison of biochemical failure definitions for permanent prostate brachytherapy

31 March 2020

1 reference

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

31 March 2020

1 reference

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

31 March 2020

1 reference

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

31 March 2020

1 reference

Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression

31 March 2020

1 reference

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

31 March 2020

1 reference

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer

31 March 2020

1 reference

Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment

31 March 2020

1 reference

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

31 March 2020

1 reference

Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma

31 March 2020

1 reference

Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer

31 March 2020

1 reference

Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer

31 March 2020

1 reference

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

31 March 2020

1 reference

Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum

31 March 2020

1 reference

Testing in Serum for Human Glandular Kallikrein 2, and Free and Total Prostate Specific Antigen in Biannual Screening for Prostate Cancer

31 March 2020

1 reference

hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.

31 March 2020

1 reference

Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer

31 March 2020

1 reference

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer

31 March 2020

1 reference

Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies

31 March 2020

1 reference

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

31 March 2020

1 reference

Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial

31 March 2020

1 reference

Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer

31 March 2020

1 reference

Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy

31 March 2020

1 reference

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial

31 March 2020

1 reference

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

31 March 2020

1 reference

Re: Prostate cancer incidence and mortality in the United States and the United Kingdom

31 March 2020

1 reference

Comparison of trends in prostate-cancer mortality in England and Wales and the USA.

31 March 2020

1 reference

Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results

31 March 2020

1 reference

Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing

31 March 2020

1 reference

An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States

31 March 2020

1 reference

Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study

31 March 2020

1 reference

The effectiveness of screening for prostate cancer: a nested case-control study.

31 March 2020

1 reference

Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality: a case-control study

31 March 2020

1 reference

Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut

31 March 2020

1 reference

Prostate cancer specific mortality in the Florence screening pilot study cohort 1992-1993

31 March 2020

1 reference

Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial

31 March 2020

1 reference

Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden

31 March 2020

1 reference

Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18337732%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference